Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array treatment for basal cell carcinoma of the skin.
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy Read More